Patients with diabetes have been listed as people at higher risk for severe illness from COVID-19. Moreover, the relationship between diabetes-related phenotypes and the severity of COVID-19 remains unknown. This observational study aims to to evaluate the risk of disease severity and mortality in association with diabetes in COVID-19 inpatients and identify the clinical and biological features associated with worse outcomes.
The epidemic of coronavirus disease-2019 (COVID-19), a disease caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus, rapidly spread worldwide and was declared a pandemic by the World Health Organization on 11 March 2020. It is well known that people with diabetes have increased infection risk, especially for influenza and pneumonia. Moreover, diabetes was previously reported as a major risk factor for mortality in people infected with the H1N1 pandemic influenza and, more recently, with the Middle East respiratory syndrome-related coronavirus (MERS-CoV) . Epidemiological studies have quickly and consistently pointed out diabetes as one of the major comorbidities associated with COVID-19 and affecting its severity. The prevalence of diabetes in patients with COVID-19 was first reported to range from 5% to 20%. Furthermore, the COVID-19-Associated Hospitalisation Surveillance Network (COVID-NET) reported a diabetes prevalence of 28.3% in hospitalised patients in the USA. More importantly, all studies published so far have reported a two- to threefold higher prevalence of diabetes in patients in ICUs compared with those with less severe disease and an increased mortality in people with diabetes. A recent meta-analysis further demonstrated that diabetes was associated with a more than doubled risk for ICU admission and a more than tripled risk for death. However, precise data regarding diabetes characteristics in hospitalised people with COVID-19 are still lacking. Moreover, the relationship between diabetes-related phenotypes and the severity of COVID-19 remains unknown. This study aims to identify the clinical and biological features and potential interactions of diabetic therapies associated with disease severity and mortality risk in people hospitalised for COVID-19. Hospital medical records of inpatients, hospitalized between February 23 to March 31 2020, at the Internal Medicine Unit dedicated to COVID-19 in the Academic Hospital of Parma, Italy will be analysed.
Study Type
OBSERVATIONAL
Enrollment
757
Endocrinology and metabolic diseases Unit
Parma, Italy
prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients
to assess risk of intensive care unit admission and/or death among COVID-19 inpatients
Time frame: february 23 to march 31, 2020
prevalence of death among COVID-19 inpatients with and without diabetes
to compare risk of death among inpatients in presence or absence of diabetes
Time frame: february 23 to march 31, 2020
prevalence of intensive care unit admission among COVID-19 inpatients with and without diabetes
to compare intensive care unit admission among inpatients in presence or absence of diabetes
Time frame: february 23 to march 31, 2020
demographic and clinical characteristics (age,gender, comorbidity status) and death and/or intensive care unit admission during hospitalization
to identify socio-demographic as predictors of severe prognosis (death or intensive care unit admission) during hospitalization
Time frame: february 23 to march 31, 2020
laboratory parameters (glycated hemoglobin, glucose at admission, renal and liver function markers, blood count, inflammatory markers, hemostasis) and death and/or intensive care unit admission during hospitalization
to identify laboratory variables as predictors of severe prognosis (death or intensive care unit admission) during hospitalization
Time frame: february 23 to march 31, 2020
pharmacological therapies and death and/or intensive care unit admission during hospitalization
to identify pharmacological therapies as predictors of severe prognosis (death or intensive care unit admission) during hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: february 23 to march 31, 2020
number of days of hospitalization in patients with and without diabetes
to compare total length of hospitalization in patients with or without diabetes
Time frame: february 23 to march 31, 2020